Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it. - 2'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- 3People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- 4Travels to Dream Objections in Europe
- 5Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Investigating Inside Plan and Home Style: Change Your Residing Space
- Dental Embed Innovation: An Achievement in Helpful Dentistry
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
- The Main 20 Gaming Control center Ever
- The race is on to turn your body into a GLP-1 factory
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- How do my eyes adjust to the dark and how long does it take?
- An Extended period of Voyaging Carefully: the World with Reason
